Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0SP3D
|
||||
| Former ID |
DAP000852
|
||||
| Drug Name |
Dihydroergotoxine
|
||||
| Synonyms |
Agit; Angionorm; Dehydroergotamine; Dergotamine; Diergo; Dihidroergotamina; Dihydergot; Dihydroergotamine; Dihydroergotaminum; Dihydroergotoxin; Diidroergotamina; Dirgotarl; Endophleban; Ergomimet; Ergont; Ergotonin; Ikaran; Migranal; Morena; Neomigran; Orstanorm; Seglor; Tonopres; Verladyn; DET MS; Dihydroergotamine methanesulfonate; Diidroergotamina [DCIT]; Ergoloid dihydroergotoxine; Co-Dergocrine; DHE-45; Dihidroergotamina [INN-Spanish]; Dihydroergotamine (INN); Dihydroergotaminum [INN-Latin]; Ergoloid Mesylates (dihydroergotoxine); Ergot Alkaloids, Hydrogenated; Neomigran (TN); Ergotamine, dihydro, methanesulfonate (salt); (10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; (5'alpha)-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; (5'alpha)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman; 5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; 9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; 9,10-Dihydroergotamine; 9,10-dihydro-ergotamine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Approved | [1] | ||
| Therapeutic Class |
Vasodilator Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C34H41N5O8S
|
||||
| Canonical SMILES |
CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5C<br />C6C(CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O
|
||||
| InChI |
1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)
|
||||
| InChIKey |
ADYPXRFPBQGGAH-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 11032-41-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
C04AE01; N02CA01
|
||||
| Target and Pathway | |||||
| Target(s) | Glutamate receptor AMPA subtype | Target Info | Agonist | [1] | |
| D(2) dopamine receptor | Target Info | Agonist | [1] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.